-

Simpson Interventions Announces Appointment of Dr. Joseph Knight as CEO

Prior CEO and Founder, Dr. John Simpson, to Remain with Company as Chief Medical Officer and Continue his Role as Chairman of the Board of Directors

original New Simpson Interventions CEO, Dr. Joseph Knight (Photo: Business Wire)

New Simpson Interventions CEO, Dr. Joseph Knight (Photo: Business Wire)

CAMPBELL, Calif.--(BUSINESS WIRE)--Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced the appointment of Dr. Joseph Knight to the role of Chief Executive Officer, effective May 1st, 2024. He replaces Simpson Interventions’ Founder and previous CEO, Dr. John B. Simpson, who will continue in his role as Chairman of the company’s Board of Directors, while additionally assuming the role of Chief Medical Officer. Dr. Simpson has been CEO since the founding of Simpson Interventions in 2019.

Dr. Knight’s extensive academic credentials include a Ph.D. from the Swiss Federal Institute of Technology (ETH Zurich), an MBA in entrepreneurship and marketing form Duke University’s Fuqua School of Business, a Bachelor and Masters in engineering from the University of South Florida and as a Fellow in Stanford University’s Biodesign Innovation Program. Dr. Knight most recently served as President and CEO of InnAVasc Medical until the company was acquired by W. L. Gore & Associates. Additionally, Dr. Knight has been part of the intellectual property development, business, and strategic planning for multiple early-stage ventures – including iRhythm Technologies, Lacuna Medial, Higgs Boson Health and Medici Medical Technologies. Dr. Knight also spent five years at Medtronic in various marketing, business development, and strategy roles.

“I’m thrilled to take the leadership mantle from Dr. Simpson, who has been a luminary in the field of cardiovascular medicine for generations,” said Dr. Knight. “Not only has Dr. Simpson grown Simpson Interventions into a company at the forefront of breakthroughs in interventional cardiology (IC), but he’s also had the foresight to tackle the complex problems that have plagued the interventional cardiology community for decades. I’m honored to be able to follow in his footsteps and lead this great company forward.”

“I’ve always believed my strength lies in taking a company from the ‘device drawing on a napkin’ phase to the ‘First in Human’ phase,” said Dr. John B. Simpson, Ph.D., M.D., founder and previous CEO of Simpson Interventions, Inc. “Now that we have reached this critical milestone, it is the perfect time to bring in a leader with the operational expertise to guide us through the next stages of growth. Dr. Knight is exceptionally well-suited for this role, and I am thrilled to support him as Chief Medical Officer while we continue to revolutionize interventional cardiology together. His story is profoundly inspiring, and I am confident he will lead Simpson Interventions to new heights.”

For more information about Simpson Interventions and its innovative medical technologies, please visit www.simpsonint.com.

About Simpson Interventions:

Simpson Interventions is a leading medical technology company committed to addressing unmet clinical needs in cardiovascular diseases through technological innovations in visual-guidance, enhanced intelligence, and electromechanical automation for minimally invasive percutaneous intervention.

For more information: www.simpsonint.com

Contacts

Steve Kelly
Simpson Interventions
Email: stevek@simpsonint.com

Industry:

Simpson Interventions, Inc.

Release Versions
English

Contacts

Steve Kelly
Simpson Interventions
Email: stevek@simpsonint.com

More News From Simpson Interventions, Inc.

Simpson Interventions Announces both IDE approval from FDA for Acolyte™ Catheter System and 510(k) clearance for its Shadow Catheter™, adds Board Member

CAMPBELL, Calif.--(BUSINESS WIRE)--Simpson Interventions, Inc., a pioneering medical technology company, specializing in cardiovascular interventional devices, today announced achievement of major development milestones. Its truly unique Acolyte™ Image-Guided Crossing and Re-Entry Catheter System has been granted an Investigational Device Exemption by the U.S. Food and Drug Administration (FDA), after having been designated as a Breakthrough Device earlier this year. Additionally, the company a...

Simpson Interventions Accepted into FDA's TAP Pilot Program for Breakthrough Device, Acolyte™ Catheter System

CAMPBELL, Calif.--(BUSINESS WIRE)--Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced its acceptance into the Total Product Life Cycle Advisory Program Pilot (TAP Pilot) by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). Only devices granted Breakthrough Device designation by the FDA may apply to enroll in the TAP Pilot Program. This voluntary program is...

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

CAMPBELL, Calif.--(BUSINESS WIRE)--Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The Acolyte Image Guided Crossing and Re-Entry Catheter System is designed to facilitate the placement and positioning of guidewires and cathete...
Back to Newsroom